Dr. Howard Smith Oncall

  Vidcast:  https://youtu.be/B1f61kbDUtk   Moderna now announces that two 25 ug doses of its mRNA vaccine triggers a robust anti-CoVid antibody response in children 6 months to 6 years of age without creating significant side effects including the worrisome myocarditis.  Comparing the antibody levels induced with those measured in Moderna-vaccinated young adults, they were the same for children 2 to 6 years and 30% greater for children 6 months to 2 years.   The vaccine efficiency for preventing any CoVid infection, mainly Omicron, was 44% for the infant-toddler group and 38% for the 2 to 6 year olds.  hese are similar to the infection-prevention stats for older subjects.  Since all infections that occurred were mild, no vaccine efficiencies for prevention of serious or deadly CoVid could be calculated.   Moderna plans to ramp up its vaccine availability for American children and teens by obtaining Emergency Use Authorizations for all ages 6 months to 18 years.  Children would be able to receive both primary